Clinical Trial Update: A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer [Phase 3]

View source ↗

Summary

This Phase 3 trial is evaluating rilvegostomig in combination with a fluoropyrimidine and trastuzumab deruxtecan as first-line therapy for HER2-positive gastric…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Rilvegostomig (rilvegostomig)
• Trastuzumab deruxtecan (trastuzumab deruxtecan)
• fluoropyrimidine (fluoropyrimidine)

Snippet

Sponsor: AstraZeneca | Conditions: HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Status: RECRUITING